ARCHIVES

NCI Exceeded Mandate In Study Of Legislators, Rep. Porter Says

This article is from The Cancer Letter archive.

Vol. 21 No. 32 | August 11, 1995

Download PDF Visit The Full Archive

Related Articles

Phase III Trial of ThermoDox Fails to Meet Primary Endpoint

February 22, 2013

Commercial Firms Get Foot In The Door With CREG, But Won’t Be Permitted To Make Money On Grants

January 10, 1975

NCI Seeks $5.799 Billion In FY08 Bypass Budget

November 17, 2006

Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.

October 14, 2005

Women Are Less Active After A Diagnosis of Breast Cancer

March 28, 2003

FDA Hears More Criticism On Cancer Drug Endpoints; Joint Conferences On Criteria Recommended

July 28, 1989